Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Louis MH"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Louis MH; Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium., Berquin A; Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium.; Department of Physical and Rehabilitation Medicine, Cliniques Universitaires UCL Saint-Luc, Brussels, Belgium., Steyaert A; Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium.; Department of Anaesthesiology, Cliniques Universitaires UCL Saint-Luc, Brussels, Belgium.
Publikováno v:
British journal of pain [Br J Pain] 2023 Jun; Vol. 17 (3), pp. 293-305. Date of Electronic Publication: 2023 Jan 19.
Autor:
Louis MH; Institute of Neuroscience, Université catholique de Louvain, Brussels, Belgium., Meyer C; CHU UCL Namur site Godinne, Department of Physical Medicine and Rehabilitation, Yvoir, Belgium., Legrain V; Institute of Neuroscience, Université catholique de Louvain, Brussels, Belgium.; Psychological Sciences Research Institute, Université catholique de Louvain, Louvain-la-Neuve, Belgium.; Louvain Bionics, Université catholique de Louvain, Louvain-la-Neuve, Belgium., Berquin A; Institute of Neuroscience, Université catholique de Louvain, Brussels, Belgium.; Cliniques Universitaires UCL Saint-Luc, Department of Physical and Rehabilitation Medicine, Brussels, Belgium.
Publikováno v:
European journal of pain (London, England) [Eur J Pain] 2023 Mar; Vol. 27 (3), pp. 338-352. Date of Electronic Publication: 2022 Dec 25.
Autor:
Pierre-Louis MH; Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USA., Rouzier V; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Rivera V; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Systrom HK; Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USA., Julma P; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Jean E; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Francois LC; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Pape JW; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Ocheretina O; Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti., Wright PF; Division of Infectious Disease and International Health, Dartmouth Hitchcock Medical Center, Lebanon New Hampshire, USA.
Publikováno v:
Journal of the Pediatric Infectious Diseases Society [J Pediatric Infect Dis Soc] 2021 Feb 13; Vol. 10 (1), pp. 22-26.
Autor:
Vernon M; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France., Lambert B; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France.; CNRS, Normandy Regional Delegation, Caen, France., Meryet-Figuière M; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France., Brotin E; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France.; ImpedanCELL core facility, Federative Structure 4206 ICORE, UNICAEN, Caen, France., Weiswald LB; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France., Paysant H; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France., Vigneron N; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France., Wambecke A; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France., Abeilard E; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France.; ImpedanCELL core facility, Federative Structure 4206 ICORE, UNICAEN, Caen, France., Giffard F; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France., Louis MH; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France., Blanc-Fournier C; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France.; Biopathology Department, UNICANCER, Cancer Center F. Baclesse, Caen, France., Gauduchon P; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France., Poulain L; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France.; ImpedanCELL core facility, Federative Structure 4206 ICORE, UNICAEN, Caen, France., Denoyelle C; Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France. c.denoyelle@baclesse.unicancer.fr.; UNICANCER, Cancer Center François Baclesse, Caen, France.; ImpedanCELL core facility, Federative Structure 4206 ICORE, UNICAEN, Caen, France.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2020 Jul; Vol. 19 (7), pp. 1506-1519. Date of Electronic Publication: 2020 May 05.
Autor:
Florent R; Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Axis (Biology and Innovative Therapeutics for Ovarian Cancers), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France., Weiswald LB; Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Axis (Biology and Innovative Therapeutics for Ovarian Cancers), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France., Lambert B; Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Axis (Biology and Innovative Therapeutics for Ovarian Cancers), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France.; CNRS-Regional Delegation of Normandy, Caen, France., Brotin E; Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Axis (Biology and Innovative Therapeutics for Ovarian Cancers), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France., Abeilard E; Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Axis (Biology and Innovative Therapeutics for Ovarian Cancers), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France., Louis MH; Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Axis (Biology and Innovative Therapeutics for Ovarian Cancers), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France., Babin G; Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Axis (Biology and Innovative Therapeutics for Ovarian Cancers), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France., Poulain L; Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Axis (Biology and Innovative Therapeutics for Ovarian Cancers), Caen, France.; UNICANCER, Cancer Center François Baclesse, Caen, France.; Biological Ressources Center «OvaRessources», Cancer Center François Baclesse, Caen, France., N'Diaye M; Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Axis (Biology and Innovative Therapeutics for Ovarian Cancers), Caen, France. monique.ndiaye@unicaen.fr.; UNICANCER, Cancer Center François Baclesse, Caen, France. monique.ndiaye@unicaen.fr.
Publikováno v:
Cell death & disease [Cell Death Dis] 2020 May 18; Vol. 11 (5), pp. 380. Date of Electronic Publication: 2020 May 18.
Autor:
Vigneron N; Normandie Université, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France.; UNICANCER, Cancer Center F. Baclesse, Caen, France., Vernon M; Normandie Université, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France.; UNICANCER, Cancer Center F. Baclesse, Caen, France., Meryet-Figuière M; Normandie Université, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France.; UNICANCER, Cancer Center F. Baclesse, Caen, France., Lambert B; Normandie Université, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France.; UNICANCER, Cancer Center F. Baclesse, Caen, France.; CNRS, Normandy Delegation, France., Briand M; Normandie Université, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France.; UNICANCER, Cancer Center F. Baclesse, Caen, France., Louis MH; Normandie Université, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France.; UNICANCER, Cancer Center F. Baclesse, Caen, France., Krieger S; UNICANCER, Cancer Center F. Baclesse, Caen, France.; UNICANCER, Cancer Center F. Baclesse, Biopathology Department, Caen, France.; Normandie Université, UNIROUEN, Inserm U1245, Normandy Center for Genomic and Personalized Medicine, Rouen, France., Joly F; Normandie Université, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France.; UNICANCER, Cancer Center F. Baclesse, Caen, France.; UNICANCER, Cancer Center F. Baclesse, Medical Oncology Department and Clinical Research Unit, Caen, France., Lheureux S; Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, ON, Canada., Blanc-Fournier C; UNICANCER, Cancer Center F. Baclesse, Caen, France.; UNICANCER, Cancer Center F. Baclesse, Biopathology Department, Caen, France., Gauduchon P; Normandie Université, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France.; UNICANCER, Cancer Center F. Baclesse, Caen, France., Poulain L; Normandie Université, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France.; UNICANCER, Cancer Center F. Baclesse, Caen, France., Denoyelle C; Normandie Université, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France.; UNICANCER, Cancer Center F. Baclesse, Caen, France.
Publikováno v:
Clinical chemistry [Clin Chem] 2020 Feb 01; Vol. 66 (2), pp. 352-362.
Autor:
Bonnefond ML; Normandie University, UNICAEN, INSERM U1086 ANTICIPE, Interdisciplinary Research Unit for Cancer Prevention and Treatment, BioTICLA Axis, Biology and Innovative Therapeutics for Ovarian Cancers, Caen, France.; UNICANCER, François Baclesse Cancer Center, BioTICLA Laboratory, Caen, France., Florent R; Normandie University, UNICAEN, INSERM U1086 ANTICIPE, Interdisciplinary Research Unit for Cancer Prevention and Treatment, BioTICLA Axis, Biology and Innovative Therapeutics for Ovarian Cancers, Caen, France.; UNICANCER, François Baclesse Cancer Center, BioTICLA Laboratory, Caen, France., Lenoir S; Normandie University, UNICAEN, INSERM UMR-S 1237, Physiopathologie et Imagerie des Troubles Neurologiques (PhIND), tPA and Neurovascular Disorders Team, Caen, France., Lambert B; Normandie University, UNICAEN, INSERM U1086 ANTICIPE, Interdisciplinary Research Unit for Cancer Prevention and Treatment, BioTICLA Axis, Biology and Innovative Therapeutics for Ovarian Cancers, Caen, France.; UNICANCER, François Baclesse Cancer Center, BioTICLA Laboratory, Caen, France.; Délégation Régionale de Normandie, CNRS, Caen, France., Abeilard E; Normandie University, UNICAEN, INSERM U1086 ANTICIPE, Interdisciplinary Research Unit for Cancer Prevention and Treatment, BioTICLA Axis, Biology and Innovative Therapeutics for Ovarian Cancers, Caen, France.; UNICANCER, François Baclesse Cancer Center, BioTICLA Laboratory, Caen, France., Giffard F; Normandie University, UNICAEN, INSERM U1086 ANTICIPE, Interdisciplinary Research Unit for Cancer Prevention and Treatment, BioTICLA Axis, Biology and Innovative Therapeutics for Ovarian Cancers, Caen, France.; UNICANCER, François Baclesse Cancer Center, BioTICLA Laboratory, Caen, France., Louis MH; Normandie University, UNICAEN, INSERM U1086 ANTICIPE, Interdisciplinary Research Unit for Cancer Prevention and Treatment, BioTICLA Axis, Biology and Innovative Therapeutics for Ovarian Cancers, Caen, France.; UNICANCER, François Baclesse Cancer Center, BioTICLA Laboratory, Caen, France., Elie N; Normandie University, UNICAEN, INSERM U1086 ANTICIPE, Interdisciplinary Research Unit for Cancer Prevention and Treatment, BioTICLA Axis, Biology and Innovative Therapeutics for Ovarian Cancers, Caen, France.; Normandie University, UNICAEN, Centre de Microscopie Appliqué à la Biologie, CMabio3, Structure Fédérative 4206 ICORE, Caen, France., Briand M; Normandie University, UNICAEN, INSERM U1086 ANTICIPE, Interdisciplinary Research Unit for Cancer Prevention and Treatment, BioTICLA Axis, Biology and Innovative Therapeutics for Ovarian Cancers, Caen, France.; UNICANCER, François Baclesse Cancer Center, BioTICLA Laboratory, Caen, France.; Centre de Ressources Biologiques, OvaRessources, François Baclesse Cancer Center, Caen, France., Vivien D; Normandie University, UNICAEN, INSERM UMR-S 1237, Physiopathologie et Imagerie des Troubles Neurologiques (PhIND), tPA and Neurovascular Disorders Team, Caen, France., Poulain L; Normandie University, UNICAEN, INSERM U1086 ANTICIPE, Interdisciplinary Research Unit for Cancer Prevention and Treatment, BioTICLA Axis, Biology and Innovative Therapeutics for Ovarian Cancers, Caen, France.; UNICANCER, François Baclesse Cancer Center, BioTICLA Laboratory, Caen, France., Gauduchon P; Normandie University, UNICAEN, INSERM U1086 ANTICIPE, Interdisciplinary Research Unit for Cancer Prevention and Treatment, BioTICLA Axis, Biology and Innovative Therapeutics for Ovarian Cancers, Caen, France.; UNICANCER, François Baclesse Cancer Center, BioTICLA Laboratory, Caen, France., N'Diaye M; Normandie University, UNICAEN, INSERM U1086 ANTICIPE, Interdisciplinary Research Unit for Cancer Prevention and Treatment, BioTICLA Axis, Biology and Innovative Therapeutics for Ovarian Cancers, Caen, France.; UNICANCER, François Baclesse Cancer Center, BioTICLA Laboratory, Caen, France.
Publikováno v:
Oncotarget [Oncotarget] 2018 Sep 21; Vol. 9 (74), pp. 33896-33911. Date of Electronic Publication: 2018 Sep 21 (Print Publication: 2018).
Autor:
Meryet-Figuière M; INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France., Lecerf C; INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France., Varin E; INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France., Coll JL; INSERM U1209, Institute of Advanced Biosciences, Institut pour l'Avancée des Biosciences, Centre de Recherche UGA, Site Santé, 38700 La Tronche, France., Louis MH; INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France., Dutoit S; INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France., Giffard F; INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France., Blanc-Fournier C; INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France., Hedir S; INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France., Vigneron N; INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France., Brotin E; INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France., Pelletier L; INSERM U836, Grenoble Institute of Neurosciences, Bâtiment Edmond J. Safra, Chemin Fortuné Ferrini, Site Santé, 38706 La Tronche Cedex, France., Josserand V; INSERM U1209, Institute of Advanced Biosciences, Institut pour l'Avancée des Biosciences, Centre de Recherche UGA, Site Santé, 38700 La Tronche, France., Denoyelle C; INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France., Poulain L; INSERM U1086 'ANTICIPE' Interdisciplinary Research Unit for Cancer Prevention and Treatment, Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers' (BioTICLA), Comprehensive Cancer Center François Baclesse, 14076 Caen Cedex 5, France.
Publikováno v:
Oncology reports [Oncol Rep] 2017 Oct; Vol. 38 (4), pp. 1949-1958. Date of Electronic Publication: 2017 Aug 04.
Autor:
Pétigny-Lechartier C; Normandie Université, UNICAEN, INSERM U1199 (BioTICLA), Centre François Baclesse 'Biology and Innovative Therapeutics for Locally Agressive Cancers' (BioTICLA), Caen, France.; Comprehensive Cancer Centre François Baclesse, UNICANCER, Caen, France., Duboc C; Normandie Université, UNICAEN, INSERM U1199 (BioTICLA), Centre François Baclesse 'Biology and Innovative Therapeutics for Locally Agressive Cancers' (BioTICLA), Caen, France.; Comprehensive Cancer Centre François Baclesse, UNICANCER, Caen, France., Jebahi A; Normandie Université, UNICAEN, INSERM U1199 (BioTICLA), Centre François Baclesse 'Biology and Innovative Therapeutics for Locally Agressive Cancers' (BioTICLA), Caen, France.; Comprehensive Cancer Centre François Baclesse, UNICANCER, Caen, France., Louis MH; Normandie Université, UNICAEN, INSERM U1199 (BioTICLA), Centre François Baclesse 'Biology and Innovative Therapeutics for Locally Agressive Cancers' (BioTICLA), Caen, France.; Comprehensive Cancer Centre François Baclesse, UNICANCER, Caen, France., Abeilard E; Normandie Université, UNICAEN, INSERM U1199 (BioTICLA), Centre François Baclesse 'Biology and Innovative Therapeutics for Locally Agressive Cancers' (BioTICLA), Caen, France.; Comprehensive Cancer Centre François Baclesse, UNICANCER, Caen, France., Denoyelle C; Normandie Université, UNICAEN, INSERM U1199 (BioTICLA), Centre François Baclesse 'Biology and Innovative Therapeutics for Locally Agressive Cancers' (BioTICLA), Caen, France.; Comprehensive Cancer Centre François Baclesse, UNICANCER, Caen, France., Gauduchon P; Normandie Université, UNICAEN, INSERM U1199 (BioTICLA), Centre François Baclesse 'Biology and Innovative Therapeutics for Locally Agressive Cancers' (BioTICLA), Caen, France.; Comprehensive Cancer Centre François Baclesse, UNICANCER, Caen, France., Poulain L; Normandie Université, UNICAEN, INSERM U1199 (BioTICLA), Centre François Baclesse 'Biology and Innovative Therapeutics for Locally Agressive Cancers' (BioTICLA), Caen, France.; Comprehensive Cancer Centre François Baclesse, UNICANCER, Caen, France., Villedieu M; Normandie Université, UNICAEN, INSERM U1199 (BioTICLA), Centre François Baclesse 'Biology and Innovative Therapeutics for Locally Agressive Cancers' (BioTICLA), Caen, France. m.villedieu@baclesse.unicancer.fr.; Comprehensive Cancer Centre François Baclesse, UNICANCER, Caen, France.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2017 Jan; Vol. 16 (1), pp. 102-115. Date of Electronic Publication: 2016 Dec 15.